Richard Aranda
Gossamer Bio USA, Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Richard Aranda as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:37 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07181382 · Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)GB002, Inc. · suspended · Pulmonary Hypertension Associated With Interstitial Lung Disease · study director
- Ph3NCT06274801 · Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)Gossamer Bio USA, Inc. · recruiting · Pulmonary Arterial Hypertension · study director
- Ph3NCT05934526 · Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)GB002, Inc. · completed · Pulmonary Arterial Hypertension · study director
- Ph2NCT04456998 · GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. · completed · Pulmonary Artery Hypertension · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:37 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:37 UTC. The ranking covers the 200 most relevant of 26 PubMed records, and a shared surname and initials can bring in a namesake. All 26 on PubMed
- Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.N Engl J Med · 2005966 citationsRCR 20.5
- 414 citationsRCR 11.4
- Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.N Engl J Med · 2016389 citationsRCR 14.1
- Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.Arthritis Rheum · 2005360 citationsRCR 7.8
- 289 citationsRCR 7.2
- RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.Gastroenterology · 2019224 citationsRCR 10.6
- MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.Cancer Discov · 2023209 citationsRCR 15.8
- 205 citationsRCR 5.5
- Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.Arthritis Rheum · 2011160 citationsRCR 4.6
- Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.Clin Cancer Res · 2017130 citationsRCR 3.9